Zobrazeno 1 - 10
of 711
pro vyhledávání: '"Andrew K. Godwin"'
Autor:
David Standing, Prasad Dandawate, Sumedha Gunewardena, Obdulia Covarrubias-Zambrano, Katherine F. Roby, Dineo Khabele, Andrea Jewell, Ossama Tawfik, Stefan H. Bossmann, Andrew K. Godwin, Scott J. Weir, Roy A. Jensen, Shrikant Anant
Publikováno v:
Cell Death and Disease, Vol 15, Iss 5, Pp 1-16 (2024)
Abstract Advanced epithelial ovarian cancer (EOC) survival rates are dishearteningly low, with ~25% surviving beyond 5 years. Evidence suggests that cancer stem cells contribute to acquired chemoresistance and tumor recurrence. Here, we show that IRA
Externí odkaz:
https://doaj.org/article/a34cd1f4ae354f69b2bfaed9395015fa
Autor:
Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind Phadnis, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Weijing Sun, Stephen Williamson, Yu-Chiao Chiu, Hatice Ulku Osmanbeyoglu, Rashna Madan, Hassan Abushukair, Kelly Mulvaney, Andrew K. Godwin, Azhar Saeed
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results. 29 patients were evaluable. 100% had confirmed pMMR/MSS t
Externí odkaz:
https://doaj.org/article/ef214cc1e88d4bb382653082f8b6a181
Autor:
Chenchen He, Linlin Ma, Jeff Hirst, Fei Li, Hao Wu, Wang Liu, Jiang Zhao, Feng Xu, Andrew K. Godwin, Xiangwei Wang, Benyi Li
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionAlternol is a natural compound isolated from the fermentation of a mutated fungus. We have demonstrated its potent anti-cancer effect via the accumulation of radical oxygen species (ROS) in prostate cancer cells in vitro and in vivo. In t
Externí odkaz:
https://doaj.org/article/bb74bb9f5b694e3db95c11a1ed625183
Autor:
Christopher J. Ricketts, Aguirre A. De Cubas, Huihui Fan, Christof C. Smith, Martin Lang, Ed Reznik, Reanne Bowlby, Ewan A. Gibb, Rehan Akbani, Rameen Beroukhim, Donald P. Bottaro, Toni K. Choueiri, Richard A. Gibbs, Andrew K. Godwin, Scott Haake, A. Ari Hakimi, Elizabeth P. Henske, James J. Hsieh, Thai H. Ho, Rupa S. Kanchi, Bhavani Krishnan, David J. Kwiatkowski, Wenbin Liu, Maria J. Merino, Gordon B. Mills, Jerome Myers, Michael L. Nickerson, Victor E. Reuter, Laura S. Schmidt, C. Simon Shelley, Hui Shen, Brian Shuch, Sabina Signoretti, Ramaprasad Srinivasan, Pheroze Tamboli, George Thomas, Benjamin G. Vincent, Cathy D. Vocke, David A. Wheeler, Lixing Yang, William Y. Kim, A. Gordon Robertson, Paul T. Spellman, W. Kimryn Rathmell, W. Marston Linehan
Publikováno v:
Cell Reports, Vol 43, Iss 4, Pp 113063- (2024)
Externí odkaz:
https://doaj.org/article/53d6204d634d4e3487233c292d61e7e8
Autor:
Camille V. Trinidad, Harsh B. Pathak, Shibo Cheng, Shin-Cheng Tzeng, Rashna Madan, Mihaela E. Sardiu, Leonidas E. Bantis, Clayton Deighan, Andrea Jewell, Sagar Rayamajhi, Yong Zeng, Andrew K. Godwin
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-17 (2023)
Abstract High grade serous ovarian carcinoma (HGSOC) accounts for ~ 70% of ovarian cancer cases. Non-invasive, highly specific blood-based tests for pre-symptomatic screening in women are crucial to reducing the mortality associated with this disease
Externí odkaz:
https://doaj.org/article/798d394856234a33bc2125b451e2c7ca
Autor:
Kunwar Somesh Vikramdeo, Shashi Anand, Sarabjeet Kour Sudan, Paramahansa Pramanik, Seema Singh, Andrew K. Godwin, Ajay Pratap Singh, Santanu Dasgupta
Publikováno v:
FASEB BioAdvances, Vol 5, Iss 10, Pp 412-426 (2023)
Abstract Early detection and recurrence prediction are challenging in triple‐negative breast cancer (TNBC) patients. We aimed to develop mitochondrial DNA (mtDNA)‐based liquid biomarkers to improve TNBC management. Mitochondrial genome (MG) enric
Externí odkaz:
https://doaj.org/article/c9d72767779a4643a181e3a028f8e7f0
Autor:
Weijing Sun, Nirmal Veeramachaneni, Raed Al‐Rajabi, Rashna Madan, Anup Kasi, Mazin Al‐Kasspooles, Joaquina Baranda, Anwaar Saeed, Milind A. Phadnis, Andrew K. Godwin, Mojtaba Olyaee, Natalie Streeter, Alykhan Nagji, Junqiang Dai, Stephen Williamson
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 16098-16107 (2023)
Abstract Background Perioperative chemotherapy/chemoradiation is standard in esophageal/gastric/gastroesophageal junction (GEJ) adenocarcinoma, immune checkpoint inhibitors (ICI) effect in setting of metastatic and postoperatively. This study is to a
Externí odkaz:
https://doaj.org/article/613b6c3bdc634b1eace9ff580f7c8506
Autor:
Kristina A. Fanucci, Yalai Bai, Vasiliki Pelekanou, Zeina A. Nahleh, Saba Shafi, Sneha Burela, William E. Barlow, Priyanka Sharma, Alastair M. Thompson, Andrew K. Godwin, David L. Rimm, Gabriel N. Hortobagyi, Yihan Liu, Leona Wang, Wei Wei, Lajos Pusztai, Kim R. M. Blenman
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract We assessed the predictive value of an image analysis-based tumor-infiltrating lymphocytes (TILs) score for pathologic complete response (pCR) and event-free survival in breast cancer (BC). About 113 pretreatment samples were analyzed from p
Externí odkaz:
https://doaj.org/article/de40aac7a42e4da9b372c3f02f74cceb
Autor:
Shane R. Stecklein, Bruce F. Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M. Staley, Qamar J. Khan, Anne P. O’Dea, Lauren E. Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B. Pathak, Andrew K. Godwin, Priyanka Sharma
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and in
Externí odkaz:
https://doaj.org/article/00318f24d99f4b07bfee5dde9a0b9a2e
Autor:
Joaquina C. Baranda, Ghulam Rehman Mohyuddin, Andrés M. Bur, Yelizaveta Shnayder, Kyle R. Sweeney, Kiran Kakarala, Megan Prouty, Harsh Pathak, Rajni Puri, Amrita Mitra, Rashna Madan, M. Laird Forrest, Aric Huang, Scott Weir, Andrew K. Godwin, Nabil A. Alhakamy, J. Daniel Griffin, Cory J. Berkland
Publikováno v:
Translational Medicine Communications, Vol 8, Iss 1, Pp 1-9 (2023)
Abstract Background This window of opportunity trial evaluated the safety of intratumoral Copaxone® and profiled immune markers in biopsies before and after treatment. Methods Patients with percutaneously accessible malignancies scheduled for surgic
Externí odkaz:
https://doaj.org/article/67117a25bc5043319866b3fee0863c0e